← boardnext 2026-08next 2027-08
DFTX
Definium Therapeutics US, Inc.distress 3/10 · well-funded / low risk$43.11-1%today-11% from 52w high
Psychiatry / CNS 2
Lead: Major Depressive Disorder · est. market ~$16B (approx, global)
Revenue
pre-revenue
Liquidity
$428M
Runway
3.0 yrs
Shares 1y
+43%
Price & events
+154.0% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.3%
1D
-2.2%
1W
+19.2%
1M
+85.3%
3M
+147.8%
6M
+335.0%
1Y
+387.7%
2Y
-6.4%
5Y
-1.2%
All
Overview
- Market Cap
- $4.70B
- Enterprise Value
- $4.48B
- Volume
- 60.44K
- 52 Week Range
- $8.06 – $48.45
- Total Shares
- 109.07M
- Float Shares
- 107.08M
- Short %
- 11.01%
- % Held by Insiders
- 1.33%
- % Held by Institutions
- 65.88%
- RVOL
- 0.02x
- Beta
- 2.21
Pipeline stages · 2 programs
DT120
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
DT402 (R-enantiomer of 3, 4-methylenedioxymethamphetamine (MDMA))
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 5 trials · 3 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-08 Estimated 50% readout ~2026-10-15 | Phase 3 | DT120breakthrough | Generalized Anxiety Disorder | — | active not recruiting |
| 2027-08 Estimated 50% readout ~2027-09-15 | Phase 2 | DT402 (R-enantiomer of 3, 4-methylenedioxymethamphetamine (MDMA)) | Autism Spectrum Disorder, ASD | — | recruiting |
| 2027-09 Estimated 50% readout ~2027-11-15 | Phase 3 | DT120breakthrough | Major Depressive Disorder | — | recruiting |
| 2026-07 | Phase 3 | DT120breakthrough | Generalized Anxiety Disorder | 214 | active not recruiting |
| 2026-05-20 | Phase 3 | DT120breakthrough | Major Depressive Disorder | 149 | active not recruiting |
Upcoming readouts & decisions · our signals
1 upcoming event has our read — the sell-the-news timing call plus an experimental clinical estimate. Go Pro to see them.
Catalyst news & presentations · 12
- 2027Guided 40%trial initiationsecondaryPhase 3DT120 ODT · Initiation of Phase 3 Haven study expected in 2027SEC 8-K
- 2027Guided 40%readoutPhase 3DT120 ODT · Topline data from Ascend Phase 3 study anticipatedSEC 8-K
- 2026Guided 40%readoutPhase 3DT120 · Three Phase 3 readouts anticipated in 2026 for GAD and MDDSEC 8-K
- 2026Guided 40%readoutPhase 2DT402 · Initial data from Phase 2a study of DT402 in ASDSEC 8-K
- second half of 2026Guided 55%readoutPhase 3MM120 ODT · Topline data from Panorama studySEC 8-K
- early 3Q 2026Guided 70%readoutPhase 3DT120 ODT · Topline data from Phase 3 Voyage studySEC 8-K
- 2026-07-30Estimated 45%earningsEarningsEarnings releaseyahoo
- 2Q 2026readoutPhase 3DT120 · Topline data from Voyage Phase 3 study of DT120 ODT in GADSEC 8-K
- mid-2026trial initiationsecondaryPhase 3MM120 ODT · Initiation of Ascend studySEC 8-K
- mid-2026readoutPhase 3MM120 ODT · Topline data from Emerge study (accelerated)SEC 8-K
- 2Q 2026trial initiationsecondaryPhase 3DT120 ODT · First patient dosing anticipated in Phase 3 Ascend studySEC 8-K
- 4Q 2025trial initiationsecondaryPhase 2MM402 · Phase 2a study initiationSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $58 (+34% upside) · 15 analysts
- 2026-07-08StifelBuy
- 2026-06-30Canaccord GenuityBuy
- 2026-06-24Jones TradingBuy
- 2026-06-23BairdOutperform
- 2026-06-23NeedhamBuy
- 2026-06-22OppenheimerOutperform
Competitors — Major Depressive Disorder
- NBIXNEUROCRINE BIOSCIENCES INC$17.2B · D0
- AXSMAxsome Therapeutics, Inc.$12.3B · D0
- XENEXenon Pharmaceuticals Inc.$6.3B · D3
- SUPNSUPERNUS PHARMACEUTICALS, INC.$2.7B · D0
- BHVNBiohaven Ltd.$2.2B · D6
- SPTXSeaport Therapeutics, Inc.$1.2B · D1
- ANROAlto Neuroscience, Inc.$937M · D3
- NMRANeumora Therapeutics, Inc.$281M · D5
- HELPCYBIN INC.$175M · D5
- TNXPTonix Pharmaceuticals Holding Corp.$170M · D7
Recent news
- 2026-07-22Definium Therapeutics Inc. (DFTX) Fundamental & Financial Data - Stocktwits
- 2026-07-20Definium Therapeutics Announces New Employee Inducement Grants - The Globe and Mail
- 2026-07-20Definium Therapeutics Announces New Employee Inducement Grants - Business Wire
- 2026-07-16Definium Therapeutics Launches Wired for Worry, a Health Care Provider Initiative to Advance the Understanding of Generalized Anxiety Disorder (GAD) Patient Impact and Neurobiology - thecanadianpressnews.ca
- 2026-07-16Definium Therapeutics Launches Wired for Worry, a Health Care Provider Initiative to Advance the Understanding of Generalized Anxiety Disorder (GAD) Patient Impact and Neurobiology - Morningstar
- 2026-07-16Definium Therapeutics Launches Wired for Worry, a Health Care Provider Initiative to Advance the Understanding of Generalized Anxiety Disorder (GAD) Patient Impact and Neurobiology - Business Wire
- 2026-07-15Is Definium Therapeutics, Inc. (DFTX) Stock a Biotech Opportunity After Positive DT120 Depression Trial Data? - Yahoo Finance
- 2026-07-15Definium Therapeutics (DFTX) Could Be 30% Overvalued After New GAD Study - Sahm
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.